Want to see NMRA full AI Analyst Report?
Neumora Therapeutics, Inc. (NMRA) Income Statement
Neumora Therapeutics, Inc. Income Statement
Last quarter (Q2 2026), Neumora Therapeutics, Inc.'s total revenue was $0.00. In Q2, Neumora Therapeutics, Inc.'s net income was $-43.08M. See Neumora Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | |
| $ -5.00M | $ 0.00 | $ -668.00K | $ 0.00 | $ 0.00 | |
| $ 236.16M | $ 263.46M | $ 187.53M | $ 135.87M | $ 237.32M | |
| Depreciation and Amortization | $ 208.00K | $ 631.00K | $ 668.00K | $ 594.00K | $ 538.00K |
| $ -233.37M | $ -242.98M | $ -234.99M | $ -130.31M | $ -236.77M | |
| $ -241.16M | $ -263.46M | $ -188.19M | $ -135.87M | $ -237.32M | |
| $ 4.36M | $ 19.86M | $ -47.46M | $ 4.97M | $ 11.00K | |
| $ -236.80M | $ -243.61M | $ -235.66M | $ -130.90M | $ -237.31M | |
| $ -236.93M | $ -243.79M | $ -235.93M | $ -130.90M | $ -237.31M | |
| Per Share Metrics | |||||
| Basic EPS | $ -1.45 | $ -1.53 | $ -1.49 | $ -0.86 | $ -1.56 |
| Diluted EPS | $ -1.45 | $ -1.53 | $ -1.49 | $ -0.86 | $ -1.56 |
| Weighted Average Shares Outstanding | 163.39M | 159.38M | 158.83M | 151.95M | 151.95M |
| Weighted Average Shares Outstanding (Diluted) | 163.39M | 159.38M | 158.83M | 151.95M | 151.95M |
Currency in USD